Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Ixchelsis
Sandwich, England, United Kingdomixchelsis.com ↗
- Ownership
- Private
- Employees
- ~2
- Development stage
- Other
01
Overview
Ixchelsis has developed IX‑01, an oxytocin receptor antagonist for premature ejaculation. The drug has completed Phase 1 studies and demonstrated positive proof of concept in a study of patients with severe lifelong premature ejaculation. It is currently being evaluated in a Phase IIb dose-ranging study.
- Therapeutic areas
- Men's Health
- Modalities
- Small molecule
- Industry
- Biotech
02
Partnerships
Chorus (Eli Lilly's early phase virtual drug development arm)TVM Life Science Ventures VIIPfizer Ventures
Beyond the preview
Go deeper on Ixchelsis.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Ixchelsis.